Title:
FUSION PROTEIN AND COMPOSITION FOR TREATING ANIMAL TUMORS
Document Type and Number:
WIPO Patent Application WO/2021/008308
Kind Code:
A1
Abstract:
A fusion protein and composition for treating animal tumors. The fusion protein comprises three different gene segments. The fusion protein has a good inhibitory effect on various animal solid tumors, and is capable of shrinking tumors, or even causing same to disappear; is capable of better inhibiting the metastasis of malignant tumors; and improves the quality of life of patients to a large extent.
Inventors:
ZHANG JINYU (CN)
Application Number:
PCT/CN2020/097441
Publication Date:
January 21, 2021
Filing Date:
June 22, 2020
Export Citation:
Assignee:
BEIJING KENUOKEFU BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07K19/00; A61K38/20; A61K48/00; A61P35/00; C12N15/26
Domestic Patent References:
| WO2018184484A1 | 2018-10-11 |
Foreign References:
| US6617135B1 | 2003-09-09 | |||
| CN101495156A | 2009-07-29 | |||
| CN201810104146A | 2018-02-01 |
Other References:
ZHANG, J.Y. ET AL.: "In situ administration of cytokine combinations induces tumor regression in mice", EBIOMEDICINE, vol. 37, 5 October 2018 (2018-10-05), XP055774651
DU, X.B. ET AL.: "The therapeutic effects of intratumoral injection of IL12IL2GMCSF fusion protein on canine tumors", BIORXIV, 4 June 2020 (2020-06-04), XP055774657
ZHANG, J.Y. ET AL.: "In situ administration of cytokine combinations induces tumor regression in mice", EBIOMEDICINE, vol. 37, 5 October 2018 (2018-10-05), XP055774651
STRAUSS, J. ET AL.: "First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors", CLINICAL CANCER RESEARCH, vol. 25, no. 1,, 1 January 2019 (2019-01-01), XP009522107
ELIZABETH, O. ET AL.: "Antibody-cytokine fusion proteins: applications in cancer therapy", EXPERT OPIN BIOL THER, vol. 8, no. 5, 31 May 2008 (2008-05-31), XP008145785
WEN, Q. ET AL.: "Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 14, 31 December 2016 (2016-12-31), XP055382486
WILLIAMS, P. ET AL.: "GM-CSF-Based Fusion Cytokines as Ligands for Immune Modulation", THE JOURNAL OF IMMUNOLOGY, vol. 186, 31 December 2011 (2011-12-31), XP055142073
KONG, ZHAOYAN ET AL.: "The application of cytokines in the treatment of tumors", JOURNAL OF MODERN ONCOLOGY, vol. 22, no. 4, 1 May 2014 (2014-05-01), DOI: 20200901102741Y
See also references of EP 3998288A4
DU, X.B. ET AL.: "The therapeutic effects of intratumoral injection of IL12IL2GMCSF fusion protein on canine tumors", BIORXIV, 4 June 2020 (2020-06-04), XP055774657
ZHANG, J.Y. ET AL.: "In situ administration of cytokine combinations induces tumor regression in mice", EBIOMEDICINE, vol. 37, 5 October 2018 (2018-10-05), XP055774651
STRAUSS, J. ET AL.: "First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors", CLINICAL CANCER RESEARCH, vol. 25, no. 1,, 1 January 2019 (2019-01-01), XP009522107
ELIZABETH, O. ET AL.: "Antibody-cytokine fusion proteins: applications in cancer therapy", EXPERT OPIN BIOL THER, vol. 8, no. 5, 31 May 2008 (2008-05-31), XP008145785
WEN, Q. ET AL.: "Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 14, 31 December 2016 (2016-12-31), XP055382486
WILLIAMS, P. ET AL.: "GM-CSF-Based Fusion Cytokines as Ligands for Immune Modulation", THE JOURNAL OF IMMUNOLOGY, vol. 186, 31 December 2011 (2011-12-31), XP055142073
KONG, ZHAOYAN ET AL.: "The application of cytokines in the treatment of tumors", JOURNAL OF MODERN ONCOLOGY, vol. 22, no. 4, 1 May 2014 (2014-05-01), DOI: 20200901102741Y
See also references of EP 3998288A4
Attorney, Agent or Firm:
BEIJING WEIZHENG PATENT AGENCY CO., LTD. et al. (CN)
Download PDF:
Previous Patent: TELEVISION BASED ON PIXEL LIGHT CONTROL, PIXEL LIGHT CONTROL METHOD AND READABLE STORAGE MEDIUM
Next Patent: IMPROVED IMPACT STRUCTURE
Next Patent: IMPROVED IMPACT STRUCTURE